Multiple Sclerosis Clinical Trials in Birmingham, Alabama

11 recruitingBirmingham, Alabama

Showing 111 of 11 trials

Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.500 enrolled85 locationsNCT06433752
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Multiple Sclerosis Spasticity
Celgene200 enrolled53 locationsNCT06782490
Recruiting
Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 1

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Chronic Fatigue SyndromeHealthyMultiple Sclerosis+1 more
University of Alabama at Birmingham120 enrolled1 locationNCT03759522
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Not Applicable

Functional Outcomes From Diets in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University of Alabama at Birmingham100 enrolled2 locationsNCT05327322
Recruiting

Care in Multiple Sclerosis (MS)

Multiple Sclerosis
NYU Langone Health386 enrolled6 locationsNCT07011914
Recruiting

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

Amyotrophic Lateral SclerosisMultiple SclerosisSpinal Cord Injuries+1 more
University of Alabama at Birmingham160 enrolled1 locationNCT04721717